BioCryst Pharmaceuticals presented new results from a Phase 3 clinical trial showing that preventive treatment with oral berotralstat (…
Articles by Ana Pena, PhD
Ruconest (rhC1INH) is safe and effective as an on-demand therapy to treat acute swelling attacks, and as a short-term…
Intellia Therapeutics announced the first preclinical results supporting a gene therapy candidate for hereditary angioedema (HAE). In…
BioCryst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug…
Factors involved in blood vessel permeability — called VEGF-A, VEGF-C, and sPLA2 — may predispose people who take ACE…
BioCryst Pharmaceuticals has licensed rights to Torii Pharmaceutical for the commercialization of BCX7353 — an oral, once-daily investigational…
Short-term use of Ruconest (recombinant human C1 inhibitor) as a preventive treatment reduces the risk of hereditary angioedema (HAE)…
Firazyr (icatibant acetate) does not appear to be superior to placebo or symptomatic therapies in treating attacks of…
The case of a man with hereditary angioedema (HAE) who remained undiagnosed for…
Asphyxiation caused by head and neck angioedema — swelling and fluid accumulation in the deeper layers of the…